Cefepime Dosing for Pyelonephritis with Severe Renal Impairment
For a 70-year-old patient with pyelonephritis and serum creatinine of 6 mg/dL, administer cefepime 1 g every 24 hours intravenously, with careful monitoring for neurotoxicity.
Rationale for Dose Adjustment
With a creatinine of 6 mg/dL, this patient has severe renal impairment (estimated CrCl approximately 10-15 mL/min). The FDA label explicitly states that cefepime requires dose reduction proportional to declining creatinine clearance, as approximately 85% of the drug is renally excreted 1. The pharmacokinetic data demonstrate that half-life increases from 2.3 hours in normal renal function to 13.5 hours in patients requiring hemodialysis 1, 2.
The standard dose adjustment for CrCl 11-30 mL/min is 1 g every 24 hours 1. This maintains therapeutic concentrations while minimizing the risk of drug accumulation and neurotoxicity (encephalopathy, myoclonus, seizures), which are serious adverse events documented in geriatric patients with renal impairment receiving unadjusted doses 1.
Treatment Context for Pyelonephritis
While IDSA guidelines recommend extended-spectrum cephalosporins like cefepime for hospitalized pyelonephritis patients 3, cefepime is not the first-line agent - ceftriaxone (1 g daily) is more commonly recommended due to its once-daily dosing and lack of renal adjustment requirements 3. However, if cefepime is chosen (e.g., for suspected resistant organisms or local resistance patterns), proper dose adjustment is critical.
The guidelines emphasize that hospitalized pyelonephritis patients should receive IV therapy with agents like fluoroquinolones, aminoglycosides, extended-spectrum cephalosporins, or carbapenems, with choice based on local resistance data 3.
Critical Safety Considerations
Monitor renal function closely: The elderly are at higher risk for toxic reactions, and this patient's advanced age (70 years) combined with severe renal impairment creates substantial risk 1
Watch for neurotoxicity: Symptoms include confusion, hallucinations, myoclonus, seizures, and encephalopathy. These can be life-threatening in geriatric patients with renal impairment 1
Avoid overdosing: Accidental overdosing commonly occurs when large doses are given to patients with impaired renal function 1
Consider hemodialysis: If the patient is on or requires hemodialysis, cefepime is significantly removed during dialysis (half-life drops from 13.5 to 2.3 hours), requiring post-dialysis supplementation 1, 2
Pharmacokinetic Support
Research confirms that cefepime clearance correlates directly with creatinine clearance (CL = 0.324 L/h + 0.0551 × CrCl) 4. In severe renal impairment, volume of distribution remains stable at approximately 18-20 L, but elimination is dramatically prolonged 1, 2. The 1 g every 24-hour regimen maintains trough concentrations above MIC for most uropathogens (typically ≤2 mg/L for E. coli) while staying below neurotoxic thresholds 4.
Alternative Consideration
Given this patient's severe renal impairment and advanced age, strongly consider switching to ceftriaxone 1 g IV daily instead, which requires no renal dose adjustment and has a superior safety profile in this population 3. This eliminates the complexity of dose adjustment and reduces neurotoxicity risk while maintaining excellent coverage for typical pyelonephritis pathogens.